GT201400064A - Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes - Google Patents

Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Info

Publication number: GT201400064A
Authority: GT; Guatemala
Prior art keywords: pirid; carbamoil; ilo; tetrahydroisoquinoline; apoptosis
Prior art date: 2011-10-14

Application number

GT201400064A

Other languages

English (en)

Spanish (es)

Inventor

Le Wang

George Doherty

Xilu Wang

Zhi-Fu Tao

Milan Bruncko

Aaron R Kunzer

Michael D Wendt

Xiaohong Song

Robin Frey

Todd M Hansen

Gerard M Sullivan

Andrew Judd

Andrew Souers

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-14

Filing date

2014-04-10

Publication date

2014-12-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-10 Application filed by Abbvie Inc filed Critical Abbvie Inc

2014-12-23 Publication of GT201400064A publication Critical patent/GT201400064A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

GT201400064A 2011-10-14 2014-04-10 Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes GT201400064A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161547162P	2011-10-14	2011-10-14
CN2012079012		2012-07-23

Publications (1)

Publication Number	Publication Date
GT201400064A true GT201400064A (es)	2014-12-23

Family

ID=47116421

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GT201400064A GT201400064A (es)	2011-10-14	2014-04-10	Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Country Status (36)

Country	Link
EP (1)	EP2766361B1 (2)
JP (2)	JP6155270B2 (2)
KR (1)	KR102019643B1 (2)
AR (1)	AR088327A1 (2)
AU (2)	AU2012322698A1 (2)
BR (1)	BR112014009053B1 (2)
CA (1)	CA2851364C (2)
CL (1)	CL2014000905A1 (2)
CO (1)	CO6950476A2 (2)
CR (2)	CR20200097A (2)
CY (1)	CY1118224T1 (2)
DK (1)	DK2766361T3 (2)
DO (2)	DOP2014000070A (2)
EC (1)	ECSP14000357A (2)
ES (1)	ES2598877T3 (2)
GT (1)	GT201400064A (2)
HR (1)	HRP20161319T1 (2)
HU (1)	HUE030589T2 (2)
IL (1)	IL231856A (2)
LT (1)	LT2766361T (2)
ME (1)	ME02514B (2)
MX (1)	MX356031B (2)
MY (1)	MY172723A (2)
PE (1)	PE20141282A1 (2)
PH (2)	PH12014500729A1 (2)
PL (1)	PL2766361T3 (2)
PT (1)	PT2766361T (2)
RS (1)	RS55342B1 (2)
RU (1)	RU2625315C2 (2)
SG (1)	SG11201401279XA (2)
SI (1)	SI2766361T1 (2)
TW (1)	TWI571466B (2)
UA (1)	UA115042C2 (2)
UY (1)	UY34382A (2)
WO (1)	WO2013055897A1 (2)
ZA (1)	ZA201402556B (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8889675B2 (en)	2011-10-14	2014-11-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI561521B (en)	2011-10-14	2016-12-11	Abbvie Inc	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN113209306A (zh) *	2014-12-09	2021-08-06	艾伯维公司	具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
CN111620861A (zh) *	2014-12-09	2020-09-04	艾伯维公司	具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
CN107207553A (zh) *	2014-12-09	2017-09-26	艾伯维公司	Bcl‑xl抑制性化合物和包括其的抗体药物缀合物
CN104473923B (zh) *	2014-12-29	2016-08-17	巩春智	一种防治慢性心力衰竭的药物组合物及其应用
WO2016131100A1 (en) *	2015-02-18	2016-08-25	The Walter And Eliza Hall Institute Of Medical Research	Methods of treating infectious diseases
US10195213B2 (en)	2015-03-13	2019-02-05	Unity Biotechnology, Inc.	Chemical entities that kill senescent cells for use in treating age-related disease
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
US20200147235A1 (en) *	2016-06-08	2020-05-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
BR112018075639A2 (pt) *	2016-06-08	2019-04-09	Abbvie Inc.	conjugados de anticorpo fármaco anti-egfr
AU2017277534A1 (en) *	2016-06-08	2019-01-03	Abbvie Inc.	Anti-EGFR antibody drug conjugates
WO2017214462A2 (en) *	2016-06-08	2017-12-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
RU2018147224A (ru) *	2016-06-08	2020-07-14	Эббви Инк.	Конъюгаты антитела к egfr и лекарственного средства
JP2019524651A (ja) *	2016-06-08	2019-09-05	アッヴィ・インコーポレイテッド	抗ｃｄ９８抗体及び抗体薬物コンジュゲート
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
WO2018092064A1 (en) *	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2019000236A1 (en) *	2017-06-27	2019-01-03	Merck Sharp & Dohme Corp.	ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW202002952A (zh)	2018-03-15	2020-01-16	美商艾伯維有限公司	用於治療胰臟癌之abbv-621與抗癌劑之組合
AR119494A1 (es) *	2019-07-29	2021-12-22	Servier Lab	DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
AU2021386367A1 (en)	2020-11-24	2023-06-22	Les Laboratoires Servier	Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
JP2024505562A (ja)	2021-02-02	2024-02-06	レスラボラトイレスセルビエル	選択的ｂｃｌ－ｘｌｐｒｏｔａｃ化合物及び使用の方法
WO2023215449A1 (en) *	2022-05-06	2023-11-09	Treeline Biosciences, Inc.	Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519259A1 (en) *	2022-05-06	2025-03-12	Treeline Biosciences, Inc.	Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN119562832A (zh)	2022-05-20	2025-03-04	诺华股份有限公司	Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2023271885A1 (en)	2022-05-20	2024-12-12	Les Laboratoires Servier	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250387504A1 (en)	2022-05-20	2025-12-25	Novartis Ag	Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US20250333409A1 (en) *	2022-06-10	2025-10-30	Hitgen Inc.	Compound and use thereof in preparation of BCL-XL inhibitor
PY24103486A (es)	2023-11-22	2025-06-06	Servier Lab	Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es)	2023-11-22	2026-01-14	Novartis Ag	Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY115155A (en)	1993-09-09	2003-04-30	Upjohn Co	Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de)	1995-09-15	2004-10-07	Upjohn Co	Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en)	1999-07-30	1999-09-29	Biochemie Gmbh	Organic compounds
AU2001281817B2 (en) *	2000-06-21	2005-11-24	F. Hoffmann-La Roche Ag	Benzothiazole derivatives
CA2508947A1 (en)	2002-12-20	2004-07-15	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2005099353A2 (en)	2004-04-19	2005-10-27	Symed Labs Limited	A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en)	2004-07-20	2006-01-26	Symed Labs Limited	Novel intermediates for linezolid and related compounds
JP2008514702A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
US7514068B2 (en)	2005-09-14	2009-04-07	Concert Pharmaceuticals Inc.	Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en)	2006-10-23	2014-08-05	Concert Pharmaceuticals, Inc.	Oxazolidinone derivatives and methods of use
KR101222412B1 (ko)	2007-02-15	2013-01-15	에프. 호프만-라 로슈 아게	Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
AU2008242703B2 (en)	2007-04-19	2011-08-18	Concert Pharmaceuticals Inc.	Deuterated morpholinyl compounds
US7531685B2 (en)	2007-06-01	2009-05-12	Protia, Llc	Deuterium-enriched oxybutynin
WO2009035598A1 (en)	2007-09-10	2009-03-19	Concert Pharmaceuticals, Inc.	Deuterated pirfenidone
US20090118238A1 (en)	2007-09-17	2009-05-07	Protia, Llc	Deuterium-enriched alendronate
US20090082471A1 (en)	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched fingolimod
US20090088416A1 (en)	2007-09-26	2009-04-02	Protia, Llc	Deuterium-enriched lapaquistat
WO2009045476A1 (en)	2007-10-02	2009-04-09	Concert Pharmaceuticals, Inc.	Pyrimidinedione derivatives
WO2009051782A1 (en)	2007-10-18	2009-04-23	Concert Pharmaceuticals Inc.	Deuterated etravirine
US20090105338A1 (en)	2007-10-18	2009-04-23	Protia, Llc	Deuterium-enriched gabexate mesylate
EP2217548A1 (en)	2007-10-26	2010-08-18	Concert Pharmaceuticals Inc.	Deuterated darunavir
NZ593536A (en) *	2008-12-19	2013-07-26	Genentech Inc	Quinoline derivatives and methods of use
WO2010080503A1 (en) *	2008-12-19	2010-07-15	Genentech, Inc.	Heterocyclic compounds and methods of use
KR20110123657A (ko) *	2010-05-07	2011-11-15	에스케이케미칼주식회사	피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI561521B (en) *	2011-10-14	2016-12-11	Abbvie Inc	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

2012
- 2012-10-08 TW TW101137131A patent/TWI571466B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034382A patent/UY34382A/es unknown
- 2012-10-11 PE PE2014000506A patent/PE20141282A1/es active IP Right Grant
- 2012-10-11 AU AU2012322698A patent/AU2012322698A1/en not_active Abandoned
- 2012-10-11 HR HRP20161319TT patent/HRP20161319T1/hr unknown
- 2012-10-11 WO PCT/US2012/059720 patent/WO2013055897A1/en not_active Ceased
- 2012-10-11 PH PH1/2014/500729A patent/PH12014500729A1/en unknown
- 2012-10-11 LT LTEP12780605.7T patent/LT2766361T/lt unknown
- 2012-10-11 MX MX2014004556A patent/MX356031B/es active IP Right Grant
- 2012-10-11 RS RS20160954A patent/RS55342B1/sr unknown
- 2012-10-11 UA UAA201405089A patent/UA115042C2/uk unknown
- 2012-10-11 ME MEP-2016-227A patent/ME02514B/me unknown
- 2012-10-11 PL PL12780605T patent/PL2766361T3/pl unknown
- 2012-10-11 CA CA2851364A patent/CA2851364C/en active Active
- 2012-10-11 ES ES12780605.7T patent/ES2598877T3/es active Active
- 2012-10-11 MY MYPI2014700867A patent/MY172723A/en unknown
- 2012-10-11 HU HUE12780605A patent/HUE030589T2/en unknown
- 2012-10-11 CR CR20200097A patent/CR20200097A/es unknown
- 2012-10-11 BR BR112014009053-0A patent/BR112014009053B1/pt not_active IP Right Cessation
- 2012-10-11 EP EP12780605.7A patent/EP2766361B1/en active Active
- 2012-10-11 SI SI201230730A patent/SI2766361T1/sl unknown
- 2012-10-11 DK DK12780605.7T patent/DK2766361T3/en active
- 2012-10-11 JP JP2014535869A patent/JP6155270B2/ja active Active
- 2012-10-11 RU RU2014119250A patent/RU2625315C2/ru active
- 2012-10-11 SG SG11201401279XA patent/SG11201401279XA/en unknown
- 2012-10-11 PT PT127806057T patent/PT2766361T/pt unknown
- 2012-10-11 KR KR1020147012846A patent/KR102019643B1/ko not_active Expired - Fee Related
- 2012-10-12 AR ARP120103811A patent/AR088327A1/es active IP Right Grant
2014
- 2014-04-01 IL IL231856A patent/IL231856A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02556A patent/ZA201402556B/en unknown
- 2014-04-09 DO DO2014000070A patent/DOP2014000070A/es unknown
- 2014-04-10 CL CL2014000905A patent/CL2014000905A1/es unknown
- 2014-04-10 GT GT201400064A patent/GT201400064A/es unknown
- 2014-05-06 CR CR20140205A patent/CR20140205A/es unknown
- 2014-05-07 CO CO14097093A patent/CO6950476A2/es unknown
- 2014-05-08 EC ECIEPI2014357A patent/ECSP14000357A/es unknown
2015
- 2015-06-30 PH PH12015501498A patent/PH12015501498B1/en unknown
2016
- 2016-10-27 CY CY20161101096T patent/CY1118224T1/el unknown
2017
- 2017-04-19 JP JP2017082912A patent/JP6395893B2/ja active Active
- 2017-07-20 AU AU2017206246A patent/AU2017206246B2/en not_active Ceased
2019
- 2019-02-01 DO DO2019000022A patent/DOP2019000022A/es unknown

Also Published As

Publication number	Publication date
MX356031B (es)	2018-05-09
CO6950476A2 (es)	2014-05-20
DK2766361T3 (en)	2016-12-05
AU2012322698A1 (en)	2014-04-17
MY172723A (en)	2019-12-11
PH12014500729A1 (en)	2014-05-12
IL231856A (en)	2017-07-31
JP6395893B2 (ja)	2018-09-26
KR102019643B1 (ko)	2019-09-10
PE20141282A1 (es)	2014-10-26
MX2014004556A (es)	2014-07-09
PH12015501498B1 (en)	2018-03-14
CR20200097A (es)	2020-03-31
SI2766361T1 (sl)	2016-11-30
WO2013055897A1 (en)	2013-04-18
LT2766361T (lt)	2016-11-10
CA2851364A1 (en)	2013-04-18
AR088327A1 (es)	2014-05-28
PH12015501498A1 (en)	2015-12-14
ECSP14000357A (es)	2015-11-30
BR112014009053A2 (pt)	2017-06-13
DOP2014000070A (es)	2014-07-31
JP2014530238A (ja)	2014-11-17
DOP2019000022A (es)	2019-02-15
CA2851364C (en)	2020-03-10
HUE030589T2 (en)	2017-05-29
EP2766361A1 (en)	2014-08-20
ME02514B (me)	2017-02-20
NZ623100A (en)	2016-04-29
RU2625315C2 (ru)	2017-07-13
RU2014119250A (ru)	2015-11-20
CL2014000905A1 (es)	2014-09-22
KR20140075793A (ko)	2014-06-19
AU2017206246B2 (en)	2018-07-26
CR20140205A (es)	2014-07-17
BR112014009053B1 (pt)	2022-03-29
RS55342B1 (sr)	2017-03-31
JP6155270B2 (ja)	2017-06-28
IL231856A0 (en)	2014-05-28
TWI571466B (zh)	2017-02-21
JP2017197530A (ja)	2017-11-02
AU2017206246A1 (en)	2017-08-10
UY34382A (es)	2013-05-31
CY1118224T1 (el)	2017-06-28
UA115042C2 (uk)	2017-09-11
PT2766361T (pt)	2016-10-27
PL2766361T3 (pl)	2017-03-31
ZA201402556B (en)	2017-09-27
HK1200167A1 (zh)	2015-07-31
ES2598877T3 (es)	2017-01-30
TW201319064A (zh)	2013-05-16
SG11201401279XA (en)	2014-05-29
HRP20161319T1 (hr)	2016-12-16
EP2766361B1 (en)	2016-08-10

Publication	Publication Date	Title
GT201400064A (es)	2014-12-23	Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
GT201400066A (es)	2015-03-23	Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DOP2014000074A (es)	2014-07-15	Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DOP2016000100A (es)	2016-05-31	Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
GT201500248A (es)	2017-09-14	Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CR20120631A (es)	2013-03-19	Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes
SMT201600406B (it)	2017-01-10	Derivati della 8-carbamoil-2-(pirid-6-il-2,3-disostituito)-1,2,3,4-tetraidroisochinolina come agenti inducenti apoptosi per il trattamento del cancro e di malattie immunitarie e autoimmunitarie
MX372754B (es)	2020-06-29	Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
GT201200172A (es)	2013-11-07	Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
CU20140048A7 (es)	2014-12-26	Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
NZ719905A (en)	2019-10-25	Bicyclic heterocycle compounds and their uses in therapy
MX376008B (es)	2025-03-07	Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
SV2017005434A (es)	2017-07-19	2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY33883A (es)	2012-08-31	Novedosos derivados heterocíclicos
DOP2011000152A (es)	2011-10-31	Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
CR20160352A (es)	2016-10-20	2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
ECSP17035415A (es)	2017-08-31	2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
MX2015003701A (es)	2015-10-29	Composiciones para tratamiento.
UY35600A (es)	2015-01-30	"composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"